<DOC>
	<DOCNO>NCT01820910</DOCNO>
	<brief_summary>Objective trial establish efficacy upfront target therapy consist Chlamydophila psittaci ( Cp ) -eradicating therapy prolong administration doxycycline follow eradication monitoring antibiotic re-treatment infection re-occurrence patient newly diagnose ocular adnexae marginal zone lymphoma The primary endpoint 2-year progression-free survival ( PFS ) patient newly diagnose stage-IE lymphoma treat experimental strategy .</brief_summary>
	<brief_title>Phase II Trial First-line Doxycycline Ocular Adnexal Marginal Zone Lymphoma Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>1 . Histological diagnosis marginal zone lymphoma ocular adnexae ( OAMZL ) 2 . Single bilateral lesion ( stage IE ) localise ocular adnexae ( conjunctiva , lachrymal gland sac , orbit soft tissue , eyelid ) 3 . Absence B symptoms 4 . Previously untreated patient 5 . No systemic antibiotic therapy last three month enrolment 6 . Age &gt; 18 year 7 . ECOG PS 02 8 . Negative HIV , HBV HCV serology 9 . Adequate bone marrow , renal , hepatic function 10 . No previous concurrent malignancy exception surgically cure carcinoma situ cervix , carcinoma skin cancer without evidence disease least 5 year 11 . Absence familial , sociological geographical condition potentially hamper compliance study protocol followup schedule 12 . Sexually active patient childbearing potential must implement adequate contraceptive measure study participation 13 . No concurrent treatment experimental drug 14 . Patientsigned informed consent obtain registration 1 . Pregnant lactate woman 2 . Known allergy tetracycline 3 . Patients unwilling comply requirement followup 4 . Myasthenia gravis ( tetracycline exacerbate muscle weakness ) 5 . Systemic lupus erythematous ( tetracycline exacerbate condition ) 6 . Patients large rapidly enlarge tumor require immediate radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>